ReviewCancer science2006
Non-viral vectors for cancer therapy.
Review in Cancer science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 89 citations in OpenAlex.
- Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiers.Therapeutic innovation & regulatory science · 2026Review
- Exploring AAV-Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy.Drug delivery and translational research · 2023Review
- Targeted Liposomes: A Nonviral Gene Delivery System for Cancer Therapy.Pharmaceutics · 2022Review
- A novel peptide ligand-coated nano-siRNA-lipoplex technology for kidney targeted gene therapy.American journal of translational research · 2022Article
- Engineering Circulating Tumor Cells as Novel Cancer Theranostics.Theranostics · 2020Article
- Cationic cholesterol derivative efficiently delivers the genes: in silico and in vitro studies.Drug delivery and translational research · 2019Article
- A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol.Therapeutic delivery · 2019Article
- Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients.PloS one · 2017Article
- Antitumor and antimetastasis effects of carboplatin liposomes with polyethylene glycol-2000 on SGC-7901 gastric cell-bearing nude mice.Oncology letters · 2014Article
- Efficient delivery of plasmid DNA using cholesterol-based cationic lipids containing polyamines and ether linkages.International journal of molecular sciences · 2014Article
- Gene therapy, early promises, subsequent problems, and recent breakthroughs.Advanced pharmaceutical bulletin · 2013Article
- Update on oncolytic viral therapy - targeting angiogenesis.OncoTargets and therapy · 2013Article
- Article
- Lipothioureas as Lipids for Gene Transfection: A Review.Pharmaceuticals (Basel, Switzerland) · 2011Review
- Advancement and prospects of tumor gene therapy.Chinese journal of cancer · 2011Review
- Trafficking microenvironmental pHs of polycationic gene vectors in drug-sensitive and multidrug-resistant MCF7 breast cancer cells.Biomaterials · 2010Article
- Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.Expert opinion on drug delivery · 2010Review
- Protein kinase Calpha-responsive polymeric carrier: its application for gene delivery into human cancers.Cancer science · 2009Article
- A potential targeting gene vector based on biotinylated polyethyleneimine/avidin bioconjugates.Pharmaceutical research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers are diverse and often resistant to therapeutic strategies. Gene therapy has yet to meet the promise of a breakthrough in cancer therapy. There are several barriers to overcome in cancer gene therapy. One of the biggest challenges is the design of appropriate vectors. Numerous viral and non-viral methods for gene transfer have been developed for human gene therapy, but both viral and non-viral vectors have limitations and advantages. In this review article, recent improvements in the development of non-viral vectors for delivering gene therapy for the treatment of cancer will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.